Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease
暂无分享,去创建一个
V Kaasinen | J O Rinne | K. Någren | J. Hietala | C. Halldin | V. Oikonen | J. Rinne | L. Farde | V. Kaasinen | H. Vilkman | J Hietala | C Halldin | V Oikonen | L Farde | K Någren | H Vilkman
[1] R. C. Oldfield. The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.
[2] J. Fields,et al. Neurotransmitter receptor alterations in Parkinson's disease. , 1977, Life sciences.
[3] R. Bannister,et al. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease , 1979, Journal of the Neurological Sciences.
[4] Y Agid,et al. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.
[5] G. E. Alexander,et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.
[6] Bernard J. Ransil,et al. Associations of handedness with hair color and learning disabilities , 1987, Neuropsychologia.
[7] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[8] Y. Agid,et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.
[9] D. Weinberger,et al. Mesocortical Dopaminergic Function and Human Cognition , 1988, Annals of the New York Academy of Sciences.
[10] J. Palacios,et al. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology , 1989, Brain Research.
[11] C. Pelizzari,et al. Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.
[12] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[13] J. Rinne,et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[14] K. Någren,et al. PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease , 1990, Journal of neuroscience research.
[15] V J Cunningham,et al. Compartmental Analysis of Diprenorphine Binding to Opiate Receptors in the Rat in vivo and its Comparison with Equilibrium Data in vitro , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] Päivi Marjamäki,et al. A post-mortem study on striatal dopamine receptors in Parkinson's disease , 1991, Brain Research.
[17] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[18] M. Reivich,et al. Attention and sentence processing deficits in Parkinson's disease: the role of anterior cingulate cortex. , 1992, Cerebral cortex.
[19] D. Jewett,et al. A simple synthesis of [11C]methyl triflate. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[20] R. Myers,et al. Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.
[21] C D Marsden,et al. Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.
[22] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.
[23] U Ruotsalainen,et al. PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[24] Robert M. Kessler,et al. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.
[25] A. Antonini,et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.
[26] R. Dolan,et al. Depression in Parkinson's disease. A positron emission study. , 1994, The British journal of psychiatry : the journal of mental science.
[27] S. Dollfus,et al. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia , 1994, Biological Psychiatry.
[28] R. Coppola,et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] Ulla Ruotsalainen,et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.
[30] Thomas K. Lewellen,et al. Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .
[31] T Suhara,et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] K. Någren,et al. PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease , 1995 .
[33] T. Di Paolo,et al. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. , 1996, Molecular pharmacology.
[34] Y. Agid,et al. Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. , 1996, Brain research. Molecular brain research.
[35] D J Brooks,et al. Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] T. Yanagihara,et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease , 1996, Neurology.
[37] D. J. Brooks,et al. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias , 1997, Neurology.
[38] F. Amenta,et al. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives. , 1997, Hypertension.
[39] P. Sokoloff,et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[40] Christer Halldin,et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.
[41] J. Joyce,et al. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. , 1997, Journal of psychiatric research.
[42] J. Petter Gustavsson,et al. D2 dopamine receptors and personality traits , 1997, Nature.
[43] F. Tamaru. Disturbances in higher function in Parkinson's disease. , 1997, European neurology.
[44] J. Joyce,et al. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[45] Christer Halldin,et al. Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP[11C]flumazenil and [11C]methionine , 1998 .
[46] Victor W. Pike,et al. Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β‐CIT‐FE, by the use of [11C]methyl triflate , 1998 .
[47] A. Markham,et al. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.
[48] C. Halldin,et al. Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[49] J. Joyce,et al. Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.
[50] A. Bonnet. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.